Adage Capital Partners
FUSN

Adage Capital Partners’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Adage Capital Partners’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400,000
Closed -$3.84M – 965
2023
Q4 		$3.84M Buy
+400,000
New +$1.94M 0.01% 702

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners's FUSN Position: Q1 2024 in Review

Adage Capital Partners sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 400,000 shares — an estimated $3.84M sold.

Adage Capital Partners first reported a position in FUSN in Q4 2023 and held it in 1 quarter. The position peaked at $3.84M in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • Adage Capital Partners reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 400,000 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $3.84M.
  • Adage Capital Partners first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2023 and held it in 1 quarter.
  • Adage Capital Partners's Fusion Pharmaceuticals Inc. Common Shares position peaked at $3.84M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.